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ORIGINAL ARTICLE
Background/Aims: To characterize ultrasonographic findings in papillary thyroid carcinoma (PTC) combined
with Graves’ disease. 
Methods: Medical records and ultrasonographic findings of 1,013 patients with Graves’ disease and 3,380
patients without Graves’ disease were analyzed retrospectively. A diagnosis of PTC was based on a pathologic
examination.
Results: The frequency of hypoechogenicity was lower in patients with PTC and Graves’ disease than in
patients with PTC alone (p < 0.05). The frequency of perinodular blood flow in patients with PTC and Graves’
disease was significantly higher than in those with PTC alone (p < 0.05). PTC combined with Graves’ disease
was characterized by more ill-defined borders and less frequency of overall calcification, punctate calcification,
and heterogeneous echogenicity, although the difference was not statistically significant.  
Conclusions: Our results suggest that patients with Graves’ disease more frequently have atypical PTC findings
on ultrasonography. (Korean J Intern Med 2010;25:71-76)
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INTRODUCTION
Because thyroid ultrasonography is the most sensitive
method to detect thyroid nodules [1], cytological exami-
nation guided by ultrasonography has better diagnostic
accuracy than palpation [2]. Application of these methods
reveals many thyroid cancers that are not detected by
routine clinical examinations. Many studies have reported
ultrasonographic features suggesting thyroid cancer in
general [3-7]. 
The use of ultrasonography to evaluate the thyroid
gland has resulted in the detection of a large number of
non-palpable thyroid nodules in patients with Graves’
disease. Papillary thyroid carcinoma (PTC) often occurs
in Graves’ patients [8-10]. However, it is often difficult to 
differentiate malignant and benign nodules in this setting,
because the appearance of Graves’ disease varies on
ultrasonography [11]. 
In addition to frank neoplasm, Graves’ disease itself
may cause thyroid nodularity, due to coexisting colloid
goiter, autoimmune lymphocytic disease, degenerative-
involutional changes, and hyperplastic adenomatous
tissue [12]. Thus, the application of ultrasonography for
the detection of thyroid cancer in Graves’ patients may be
problematic in clinical practice.
The aim of this study was to characterize ultrasonographic
findings of PTC in patients with Graves’ disease. METHODS
Subjects
We retrospectively reviewed the records of 1,013 patients
with Graves’ disease (749 women, 264 men) and 3,380
patients without Graves’ disease (2,704 women, 676 men)
who underwent ultrasonographic examinations between
January 2003 and December 2007. A diagnosis of Graves’
disease was made when there was a diffuse thyroid goiter
with positive serum thyrotropin-binding inhibitory
immunoglobulin (TBII) or anti-thyroid autoantibodies in
patients with biochemical and clinical thyrotoxicosis.
None of the patients had a history of previous neck
irradiation or radioactive iodine therapy. Patients with
Hashimoto’s thyroiditis were excluded. Graves’ patients
who were euthyroid or who were treated with anti-thyroid
drugs for more than 4 weeks were excluded. The diagnosis
of PTC was based on pathologic examination of surgically
resected neoplasms. The study plan was reviewed and
approved by our institutional ethical committee.
Thyroid ultrasonography
Ultrasonography was performed using a 10-MHz
linear probe (LOGIQ 7, GE Medical Systems, Milwaukee,
WI, USA). The following ultrasonographic parameters
were assessed: nodule composition (completely solid,
predominantly solid, mixed solid and cystic, predomi-
nantly cystic, or completely cystic); echogenicity (hypoechoic,
isoechoic, or hyperechoic); homogeneity (homogeneous
or heterogeneous); calcifications (punctuate, rim, nodular,
or linear); nodule margin (welldefined or ill-defined);
nodule shape (regular or irregular); echographic dimension
(anteroposterior and transverse diameter); peripheral
hypoechoic rim (thin or thick), and nodular vascularity
(perinodular or intranodular).
We assessed nodule shape according to the ratio of the
anteroposterior dimension to the transverse dimension
(A/T ratio) as ≥ 1 or < 1. Nodule composition was classified
based on the approximate portion of the nodule that was
cystic as follows: completely solid, predominantly solid (1 -
24% cystic), mixed solid and cystic (25 - 74% cystic),
predominantly cystic (75 - 99% cystic), or completely
cystic. Echogenicity was categorized with respect to
the background of the surrounding parts of the thyroid
gland. Calcification was categorized as punctuate calci-
fication and macrocalcification. Punctuate calcifications
(microcalcifications) were defined as tiny, punctuate
hyperechoic foci that were usually less than 2 mm in size,
regardless of any posterior acoustic shadowing. Rimmed,
nodular, or linear calcifications were classified as macro-
calcifications. A hypoechoic rim was defined as a low
echoic rim surrounding the nodule. A rim greater than 2
mm was classified as thick. Vascularity, as determined by
power Doppler ultrasonographic imaging, was defined as
absent or not apparent, perinodular alone, or intra-
nodular. If both perinodular and intranodular vascularity
were identified, the nodule was characterized as having
intranodular vascularity.
Thyroid function and auto-antibody test
Serum levels of thyroid hormone (T3, free T4) and
thyroid stimulating hormone (TSH) were measured using
commercial radioimmunosorbent assay and immuno-
radiometric assay kits (CIS Bio International, Shering,
France), respectively. TBII activity was measured with a
radioreceptor assay kit (RSR Ltd., Cardiff, UK), and anti-
Thyroglobulin (Tg) and anti-Thyroid peroxidase (TPO)
antibodies with enhanced chemo-luminescence (ECL,
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Table 1. Characteristics of PTC in patients with and without Graves’ disease
Characteristics PTC without Graves’ disease PTC with Graves’ disease p value
(n = 110) (n = 41)
Age, yr 49.3 ± 11.6 48.1 ± 11.9 0.580
Male / Female 12 / 98 7 / 34 0.310
T3, ng/dL  141.3 ± 81.2 309.6 ± 183.7 < 0.001
Free T4, ng/dL  1.2 ± 0.9 4.1 ± 4.4 < 0.001
Thyroid stimulating hormone, µIU/mL  2.81 ± 1.10 < 0.01 < 0.001
Anti-thyroid peroxidase antibody (+), % - 75.9
Anti-thyroglobulin antibody (+), % - 39.8
Thyrotropin binding inhibitory immunoglobulin (+), % - 95.1
PTC, papillary thyroid carcinoma.Roche, Mannheim, Germany).  
Statistical analysis
All data are expressed as means ± SD. Statistical
analyses were performed using the SPSS software (SPSS
Inc., Chicago, IL, USA). The significance of differences in
categorical variables between groups was tested with the
chi-squared test or a linear-by-linear association.
Continuous variables were analyzed using the independent
t-test. A p value < 0.05 was deemed to indicate statistical
significance.
RESULTS
Of 3,380 patients without Graves’ disease, 110 were
diagnosed with PTC, and of 1,013 Graves’ patients, 41 were
diagnosed with PTC. Clinical and hormonal characteristics
of PTC patients with and without Graves’ disease are
shown in Table 1. PTC patients with Graves’ disease had
higher serum T3 and free T4 levels, and lower serum TSH
value than PTC patients without Graves’ disease (p <
0.001). There was no significant difference in age or
gender between the two groups, although females were
more prevalent in both groups.
We compared the ultrasonographic findings in the two
groups (Table 2). In both groups, many patients demon-
strated typical PTC findings, such as completely solid
composition, ill-defined border, peripheral hypoechoic
rim, hypoechoic echogenicity, and nodular blood flow.
Hypoechoic echogenicity was seen in about 81% of PTC
patients with Graves’ disease and in about 95% of PTC
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Table 2. Ultrasonographic findings of PTC in patients with and without Graves’ disease
Ultrasonographic finding Type PTC without Graves’ disease PTC with Graves’ disease p value
(n = 110) (n = 41)
Size, mm 10.5 ± 6.2 11.1 ± 8.1 0.623
A/T ratio < 1 69 (62.7) 26 (63.4) 0.938
≥ 1 41 (37.3) 15 (36.6)
Composition Completely solid 104 (94.5) 39 (95.1) 0.676
Predominantly solid 6 (5.5) 1 (2.4)
Mixed solid and cystic 0 (0) 1 (2.4)
Predominantly cystic / completely cystic 0 (0) 0 (0)
Nodule shape Regular 61 (55.5) 24 (58.5) 0.734
Irregular 49 (44.5) 17 (41.5)
Nodule margin Well-defined 55 (50.0) 14 (34.1) 0.820
Ill-defined 55 (50.0) 27 (65.9)
Peripheral hypoechoic rim None 98 (89.1) 34 (82.9) 0.300
Thin 4 (3.6) 2 (4.9)
Thick 8 (7.3) 5 (12.2)
Homogeneity Homogeneous 82 (74.5) 34 (82.9) 0.278
Heterogeneous 28 (25.5) 7 (17.1)
Echogenicity Hypoechoic 104 (94.5) 33 (80.5) 0.003
Isoechogenic 6 (5.5) 6 (14.6)
Hyperechoic                                                   0/110 (0)                                        2/41 (4.9)
Calcification None 67 (60.9) 28 (68.3) 0.597
Punctate 33 (30.0) 9 (22.0)
Peripheral rim 6 (5.5) 2 (4.9)
Internal rim 1 (0.9) 2 (4.9)
Nodular/linear 3 (2.7) 0 (0)
Vascularity Absent or not apparent 7 (6.4) 2 (4.9) 0.008
Perinodular  14 (12.7) 18 (43.9)
Intranodular 89 (80.9) 21 (51.2)
Values are presented as mean ± SD or number (%).
PTC, papillary thyroid carcinoma; A/T ratio, the ratio of the anteroposterior dimension to the transverse dimension.patients without Graves’ disease. The frequency of isoechoic
or hyperechoic echogenicity was higher in PTC patients
with Graves’ disease than in PTC patients without Graves’
disease (p < 0.05, Figs. 1A and 2A). The frequencies of
intranodular and perinodular blood flow in patients with
PTC and Graves’ disease were 51% and 44%, respectively,
and the frequencies of intranodular and perinodular blood
flow in patients with PTC alone was 81% and 13%,
respectively. The frequency of no nodular blood flow was
5% in PTC patients with Graves’ disease, and 6% in PTC
patients without Graves’ disease (p< 0.05, Figs. 1B and 2B).
Most of the PTCs in both groups were composed of
completely or predominantly solid elements. There was no
difference in calcification pattern between the two groups.
Compared with ultrasonographic features suggesting
malignancy formation, the frequency of hypoechogenicity
in PTC patients with Graves’ disease was lower than that
seen in PTC patients without Graves’ disease (Table 2).
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Figure 1. A 60-yr-old papillary carcinoma patient without Graves’ disease. (A) A transverse sonogram of the left thyroid lobe shows a
9-mm hypoechoic nodule. (B) The nodule has perinodular and intranodular hypervascularity.
A B
Figure 2. A 50-yr-old papillary thyroid carcinoma patient with Graves’ disease. (A) A longitudinal sonogram of the right thyroid lobe
reveals a 10-mm hyperechoic nodule. (B) The nodule has perinodular hypervascularity.
A BThe frequency of intranodular flow in PTC patients with
Graves’ disease was lower than in PTC patients without
Graves’ disease (Table 2). The frequency of perinodular
flow in PTC patients with Graves’ disease was significantly
higher than in PTC patients without Graves’ disease
(Table 2). PTC in the presence of Graves’ disease was
found to have more illdefined borders and less overall
calcification, punctate calcification, and heterogeneous
echogenicity, but not to a significant degree. There was no
significant difference regarding cystic change, peripheral
hypoechoic rim, macrocalcifications, or A/T ≥ 1 (Table 2). 
DISCUSSION
Many studies have examined ultrasonographic features
which may be helpful for differential diagnosis of benign
and malignant nodules. Thyroid echogenicity reflects the
gland’s follicular structure. Conditions that modify the
normal anatomical structure of the gland cause alterations
in echo patterns. In Graves’ disease, the echo pattern of
the thyroid may undergo changes secondary to the
reduced colloid content, with increased cellularity,
reduction in the cell-colloid interface, increased
vascularity, and lymphocytic infiltration [11]. Thus, it may
be important to characterize the ultrasono-graphic
features of PTC patients with Graves’ disease. However,
ultrasonographic findings of thyroid cancer in Graves’
disease have not yet been fully determined.
Psammoma body microcalcifications are specific to
papillary thyroid cancer [13,14]. Hypoechogenicity and an
ill-defined margin are known sonographic findings
associated with thyroid cancer [15,16]. Irregular margins,
which result from microinvasion of the surrounding
tissues, may also indicate thyroid malignancy [13]. Both
thick peripheral hypoechoic rim patterns and the absence
of a rim surrounding a thyroid nodule, which represents
pericapsular inflammatory infiltration, have been
reported to be indicators of malignancy [17]. Many studies
have demonstrated the potential utility of power Doppler
imaging in identifying thyroid nodules with a higher
probability of malignancy formation [18]. Recently,
several studies have reported that an A/T ratio ≥ 1 is
associated with thyroid malignancy [7,19].
In the present study, ultrasonographic findings of
PTC patients both with and without Graves’ disease were
typical. Hypoechogenicity, ill-defined borders, absence of
peripheral hypoechoic rim, no cystic changes, and increased
intranodular blood flow were frequently seen in both
groups. Punctate calcifications were more common than
macrocalcifications in both groups, but there was no
significant difference between the groups in this regard.
Many studies have noted that the degree of echogenicity
can be used to differentiate thyroid nodules and that
most malignant nodules are hypoechoic [16]. Ultrasonic
echogenicity of the thyroid gland depends on cellularity
and vascularization of the tissue. The hypoechogenic
image is thought to represent the cellular microfollicular
histological milieu, whereas ultrasonographic findings of
a macrofollicular nodule may be isoechoic or hyperechoic
[20]. Reduced colloid content, lymphocyte infiltration and
increased intrathyroidal flow in Graves’ disease lead to
hypoechogenic patterns [21]. Graves’ disease is also
associated with inhomogeneous echogenicity in addition
to a higher grade of hypoechogenicity [22]. In the present
study, the majority of PTCs without underlying Graves’
disease (94.5%) were hypoechoic; only 5.5% were isoechoic.
In contrast, 80.5% of PTCs with underlying Graves’ disease
were hypoechoic, 14.6% were isoechoic, and 4.9% were
hyperechoic. This finding may suggest that nonhypoechoic
echogenicity of a nodule does not necessarily indicate a low
probability of PTC in the presence of Graves’ disease.
Tumor growth is associated with cellular proliferation.
Cellular proliferation is thought to be correlated with
increased vascularization that may be widely variable, up
to anarchical angiogenesis, which is present in malignant
lesions [23]. Frates et al. [24] reported that increased
nodular blood flow was associated with thyroid carcinoma.
Carbone et al. [18] proposed that the predominant intra-
nodular blood flow observed in malignant nodules could
be explained by the large cellular proliferation in the
region. Graves’ disease exhibits increased cellularity and
an increased vascular pattern, which consists of multiple
small areas of intrathyroidal flow, seen diffusely throughout
the thyroid gland [21]. Thus, the nodular vascular pattern
in the context of Graves’ disease might be affected. In the
present study, increased intranodular blood flow was
frequently seen in PTC patients both with and without
Graves’ disease. Our results also showed that PTCs in the
presence of underlying Graves’ disease tended to exhibit
significantly increased perinodular hypervascularity
(43.9%), as compared to PTCs without underlying Graves’
disease (12.7%).
In conclusion, on ultrasonography, the frequency of
perinodular hypervascularity was significantly higher, and
the frequency of hypoechogenicity was significantly lower,
Chung JO, et al. Sonographic features of papillary cancer in Graves’ disease    75in PTC patients with Graves’ disease than in PTC patients
without Graves’ disease. Thus, our results suggest that
patients with Graves’ disease more frequently have
atypical PTC findings on ultrasonography.
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